Clariness Announces Role in Supporting YPrime's Patient and Site eCOA Initiatives
Clariness announces its support of YPrime’s ongoing commitment to enhance the patient and site eCOA experience, by delivering insights from more than 2,000 patients, in four countries, assessing patient demographics and psychographics.
Assessing the digital behaviors and trial awareness of a diverse international population, Clariness received patient insights across five therapeutic areas, including oncology, immunology, rare diseases, central nervous system, and dermatology.
Clariness was tasked with providing insights from 1,600 patients, gathering data on digital device usage behaviors, app and notification preferences, and previous trial experiences. Clariness delivered insights from over 2,000 patients, in two months, which could be segmented by patient age, medical condition, education level, ethnicity, spoken language, and more.
Reference
Clariness delivers more than 50,000 patient data points to drive YPrime’s customer experience. (2023, April 24). Clariness.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
